Final guidance suggests sponsors select two doses for Phase II trials with additional data requirements.
Matt Cooper, PhD
Advertisement
Executive Director and Therapeutic Strategy Lead, Oncology, at Worldwide Clinical Trials
Articles by Matt Cooper, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The 10 Most Powerful Study KRIs in RBQM and GCP Issues They Can Prevent
2
ACT Brief: APAC Inspection Findings, RBQM Key Risk Indicators, and Head and Neck Cancer Approval
3
How China Cut Its Phase III Startup Timeline and What Drove the Change
4
What FDA Inspections Reveal About the Quality of APAC Clinical Trial Sites
5